Pancreatic Cancer Research

ResearcherXijing HospitalActive in the last 2 years

Kaishan Tao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8573-0445; OpenAlex author ID A5059333476, A5158781278. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 3

  1. Functional Delivery of Nanoimmunotherapies in Pancreatic Ductal Adenocarcinoma: A Barrier-Informed Pharmaceutics Framework. Co-author DOI 10.3390/pharmaceutics18101305↗
  2. MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1. Co-author DOI 10.3892/or.2014.3374↗
  3. Lumican expression in pancreatic ductal adenocarcinoma. Last author DOI 10.5754/hge12642↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baodan Xu · 1 shared paper, 2026 · strength 0.43
  2. Yang Wang · 1 shared paper, 2026 · strength 0.43
  3. Dou Ke-feng · 2 shared papers, 2013–2014 · strength 0.10
  4. Desheng Wang · 1 shared paper, 2014 · strength 0.05
  5. Liang Zhou · 1 shared paper, 2014 · strength 0.05
  6. Zhao-Xu Yang · 1 shared paper, 2013 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.